PTC Therapeutics has announced that their APHENITY trial achieved its primary endpoint with sepiapterin in PKU patients. Details can be found here, and their recent presentation on results, here.  Questions? Email [email protected]. PKU News shares relevant information with the IEM community but does not endorse any company, product, or trial.

Read More